| | | | |
CUSIP No. 43157M102 | | Schedule 13G | | Page 12 of 16 |
Not applicable.
(a-c)
The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of December 31, 2023, based upon 48,437,001 shares of Common Stock outstanding as of November 6, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.
| | | | | | | | | | | | | | | | | | | | | | | | |
Reporting Person | | Amount beneficially owned | | | Percent of class | | | Sole power to vote or to direct the vote | | | Shared power to vote or to direct the vote | | | Sole power to dispose or to direct the disposition | | | Shared power to dispose or to direct the disposition | |
The Carlyle Group Inc. | | | 1,838,486 | | | | 3.8 | % | | | 0 | | | | 1,838,486 | | | | 0 | | | | 1,838,486 | |
Carlyle Holdings I GP Inc. | | | 1,838,486 | | | | 3.8 | % | | | 0 | | | | 1,838,486 | | | | 0 | | | | 1,838,486 | |
Carlyle Holdings I GP Sub L.L.C. | | | 1,838,486 | | | | 3.8 | % | | | 0 | | | | 1,838,486 | | | | 0 | | | | 1,838,486 | |
Carlyle Holdings I L.P. | | | 1,838,486 | | | | 3.8 | % | | | 0 | | | | 1,838,486 | | | | 0 | | | | 1,838,486 | |
CG Subsidiary Holdings L.L.C. | | | 1,838,486 | | | | 3.8 | % | | | 0 | | | | 1,838,486 | | | | 0 | | | | 1,838,486 | |
TC Group, L.L.C. | | | 1,838,486 | | | | 3.8 | % | | | 0 | | | | 1,838,486 | | | | 0 | | | | 1,838,486 | |
Carlyle Investment Management L.L.C. | | | 1,838,486 | | | | 3.8 | % | | | 0 | | | | 1,838,486 | | | | 0 | | | | 1,838,486 | |
Carlyle Genesis UK LLC | | | 1,838,486 | | | | 3.8 | % | | | 0 | | | | 1,838,486 | | | | 0 | | | | 1,838,486 | |
Abingworth LLP | | | 1,838,486 | | | | 3.8 | % | | | 0 | | | | 1,838,486 | | | | 0 | | | | 1,838,486 | |
Abingworth Bioventures 8 LP | | | 1,838,486 | | | | 3.8 | % | | | 0 | | | | 1,838,486 | | | | 0 | | | | 1,838,486 | |
The shares of Common Stock reported herein are held of record by Abingworth Bioventures 8 LP.
The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Abingworth Bioventures 8 LP has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by Abingworth Bioventures 8 LP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by Abingworth Bioventures 8 LP, but each disclaims beneficial ownership of such securities.